Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Succinate dehydrogenase complex flavoprotein subunit A (SDHA) is the major catalytic subunit of succinate-ubiquinone oxidoreductase (complex II of the mitochondrial respiratory chain). SDHA catalyzes the oxidation of succinate to fumarate in the citric acid (Krebs) cycle and transfers electrons to the electron transport chain, playing a crucial role in cellular energy metabolism. SDHA also participates in cell signaling as a tumor suppressor and as a regulator of the hypoxia-inducible factor (HIF) pathway by controlling succinate levels. Germline or somatic mutations in SDHA are associated with several cancers, most notably SDH-deficient gastrointestinal stromal tumors and paragangliomas, as well as metabolic and neurodegenerative disorders such as Leigh syndrome[1][2][3][4].
Small molecules or mutations can inhibit SDHA, causing succinate accumulation, impaired electron transport, and HIF stabilization, which contribute to tumorigenesis[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Succinate dehydrogenase complex flavoprotein subunit A (SDHA).